HECT and RLD domain containing E3 ubiquitin protein ligase family member 6Genealiases: []
Q-omics provides the consensus-scored HERC6 profile across patient tissues and cancer cell-line models. HERC6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HERC6 is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, HERC6 protein abundance shows 22,108 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, UCEC, and LUAD as cancer lineages where HERC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HERC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HERC6 survival associations across molecular data types. HERC6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HERC6 RNA expression–survival associations across cancer types. High HERC6 expression shows unfavorable associations in LGG, but favorable associations in SKCM, KIRC, CESC, SARC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HERC6 RNA expression.
This table summarizes HERC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in UCEC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HERC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HERC6 shows lower tumor expression in UCEC, LUSC and KICH and higher tumor expression in CHOL, COAD and HNSC. The UCEC box plot shows higher HERC6 RNA expression in normal versus tumor tissue (log2 FC = −0.789, t-test p = .011).
This table shows molecular features associated with HERC6 in patient tissues and cancer cell lines. In patient samples, HERC6 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HERC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
